Tens of thousands of postmenopausal women could benefit from a newly approved bone-strengthening medication, according to the National Institute for Health and Care Excellence (NICE).
The drug, Abaloparatide, is designed to protect against osteoporosis, a bone-thinning condition that significantly increases the risk of fractures as people age.
NICE has announced that Abaloparatide will be available on the NHS in England within the next three months. This medication, administered via a pre-filled pen that patients can self-inject daily, works by stimulating cells to produce new bone.
While there are existing treatments for osteoporosis, this new option is particularly valuable for those who have not responded well to, or cannot tolerate, other therapies.
Dr. Nicky Peel, a clinical trustee at the Royal Osteoporosis Society and a metabolic bone physician in Sheffield, stated that Abaloparatide is generally “a very well-tolerated treatment” for most people. Although some patients may experience side effects such as nausea, headaches, and palpitations, these typically occur in the early stages of treatment. Dr. Peel emphasized that Abaloparatide is suitable for most individuals at high risk of fractures.
However, Dr. Peel also noted that the key challenge lies in ensuring patients have access to “appropriate diagnostic services” to identify those who need the drug.
Patients will be considered for this treatment if their doctors assess them to be at significant risk of fractures.
Bone strength typically peaks in the mid-20s and gradually declines afterward. Severe bone loss can lead to fractures even after minor bumps or falls. Adequate intake of vitamin D and calcium is crucial for maintaining bone health, and hormone replacement therapy (HRT) around menopause can also be beneficial.
Women are particularly vulnerable to osteoporosis due to the hormonal changes that occur during menopause, especially the drop in estrogen levels, which can weaken bones.
Prof Jonathan Benger, Chief Medical Officer and Deputy Chief Executive at NICE, highlighted the impact of osteoporosis, stating, “The independent committee heard from patients about how debilitating osteoporosis can be. Our focus is on enabling access to care that improves quality of life while offering value to the taxpayer.”
